Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)

Bristol Myers Squibb (CELG-RI) reported Construction in Progress of $1.5 billion for Q1 2026, down 6.94% year-over-year from $1.7 billion in Q1 2025, and down 4.82% quarter-over-quarter from $1.6 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has 12 years of Construction in Progress data on file, last reported at $1.5 billion in Q1 2026.

  • Construction in Progress for Q1 2026 came in at $1.5 billion, down 6.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 6.94% YoY), and the FY2025 annual result was $1.6 billion, up 6.16% from the prior year.
  • Construction in Progress fell to $1.5 billion in Q1 2026 per CELG-RI's latest filing, from $1.6 billion in the prior quarter.
  • Over five years, Construction in Progress peaked at $1.8 billion in Q2 2025 and troughed at $800.0 million in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Construction in Progress.
  • The sharpest annual moves came in 2022 and 2026: Construction in Progress soared 54.14% in 2022, then declined 6.94% in 2026.
  • A 5-year view of Construction in Progress shows it stood at $1.1 billion in 2022, then grew by 2.09% to $1.1 billion in 2023, then jumped by 41.86% to $1.5 billion in 2024, then grew by 6.16% to $1.6 billion in 2025, then fell by 4.82% to $1.5 billion in 2026.
  • Business Quant data shows CELG-RI's Construction in Progress at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn -
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 1.54 Bn
10 Bristol Myers Squibb - - 8.07 Bn 1.54 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.54 Bn
Dec 31, 2025 1.62 Bn
Sep 30, 2025 1.46 Bn
Jun 30, 2025 1.76 Bn
Mar 31, 2025 1.66 Bn
Dec 31, 2024 1.53 Bn
Sep 30, 2024 1.37 Bn
Jun 30, 2024 1.26 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.08 Bn
Sep 30, 2023 1.11 Bn
Jun 30, 2023 1.20 Bn
Mar 31, 2023 1.07 Bn
Dec 31, 2022 1.05 Bn
Sep 30, 2022 973.00 Mn
Jun 30, 2022 850.00 Mn
Mar 31, 2022 800.00 Mn
Dec 31, 2021 764.00 Mn
Sep 30, 2021 695.00 Mn
Jun 30, 2021 565.00 Mn